Parenteral Nutrition Market is estimated to be valued at USD 4,548.7 Mn in 2025 and is expected to reach USD 6,939 Mn in 2032, exhibiting a compound annual growth rate (CAGR) of 6.2% from 2025 to 2032.
Parenteral nutrition market as poised for steady growth, driven by the increasing prevalence of chronic diseases, a rising geriatric population, and a greater incidence of malnutrition and premature births worldwide. The market benefits from advancements in tailored and single-dose amino acid formulations, which enhance patient outcomes and reduce complications for those unable to absorb nutrients via the gastrointestinal tract.
For instance, in November 2024, Otsuka Pharmaceutical Factory, Inc. launched "KIDPAREN Injection," the amino acid, glucose, electrolyte and multivitamin injection for high calorie parenteral nutrition of patients with chronic kidney disease.
|
Event |
Description and Impact |
|
Integration of Industry 4.0 |
|
|
Growing Elderly Population and Chronic Disease Burden |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
There is a notable shift toward advanced, patient-specific PN formulations, leveraging biotechnology and digital health technologies for improved monitoring and outcomes. Customization is becoming increasingly important as clinicians seek to tailor nutritional regimens to individual patient needs, particularly in critical care and oncology settings.
Carbohydrate-based PN products are expected to dominate the market in 2025, accounting for nearly 30% of the segment, followed by lipid emulsions at around 24.5%. Innovations in lipid formulations, such as fish oil and mixed oil emulsions, are improving patient outcomes by reducing inflammation and enhancing immune response.
Rapid technical improvements, the rise in demand for customized treatments, and the introduction of novel formulations are all contributing factors to the changing patent landscape in the parenteral nutrition industry.
According to recent market assessments, patent analysis is an essential part of thorough industry studies that take into account current research and development in fields like trace element formulations, lipid emulsions, and amino acid solutions. As businesses look to differentiate their products and meet particular clinical demands, the rise of personalized and patient-specific parenteral nutrition solutions, fueled by developments in biotechnology instuments and digital health technologies, is resulting in new patent filings.
In terms of nutrition type, the Vitamins and Trace Minerals segment is expected to contribute largest share of the parenteral nutrition market trends in 2025. Parenteral nutrition involves the intravenous administration of essential nutrients including proteins, carbohydrates, fats, vitamins, and minerals to patients who cannot absorb or ingest adequate nutrition through their gastrointestinal tract due to various medical conditions such as cancer, gastrointestinal disorders, or critical illness.
In terms of patient type, the adults segment is expected to contribute largest share of the Parenteral Nutrition market trends in 2025. This dominance is primarily driven by the high prevalence of chronic diseases such as cancer, gastrointestinal disorders, and post-operative complications among adults, which often necessitate intravenous nutritional support when oral or enteral feeding is not possible.
In terms of application type, the cancer segment is expected to contribute largest share of the Parenteral Nutrition market trends in 2025. This strong presence is driven by the high prevalence of malnutrition among cancer patients, particularly as cancer treatments often lead to reduced appetite, impaired nutrient absorption, and increased metabolic demands.
In terms of distribution channel type, the hospital pharmacies segment is expected to contribute largest share of the Parenteral Nutrition market trends in 2025. The hospital pharmacies segment plays a dominant role in the parenteral nutrition (PN) market, as most PN is administered within hospital settings under the supervision of healthcare professionals.
To learn more about this report, Download Free Sample
North America is expected to be the largest market for parenteral nutrition during the forecast period, accounting for over 37.1% of the market share in 2025. North America is expected to hold a dominant position in the global parenteral nutrition market over the forecast period, owing to the increasing number of product launches or approvals.
Asia Pacific is expected to be the second-largest market for parenteral nutrition, accounting for over 20.6% of the market share in 2025. Rapid economic development, increasing healthcare investments, and rising medical tourism in China and India will augment the regional market growth.
Growth drivers include a high prevalence of chronic diseases, an increasing elderly population, and improved healthcare infrastructure offering advanced clinical nutrition services. The U.S. market benefits from strong research and development activities, personalized nutrition approaches, and significant investments by leading companies such as ICU Medical.
India’s parenteral nutrition market is expanding due to rising awareness of malnutrition and nutrient deficiencies, especially among vulnerable populations such as children and critically ill patients. Increasing healthcare expenditure, urbanization, and growing incidences of chronic diseases are driving demand for parenteral nutrition solutions.
The growth is fueled by rapid urbanization, increasing elderly population, and rising incidences of chronic and gastrointestinal diseases requiring intravenous nutritional support. The expanding healthcare infrastructure and government initiatives to improve clinical nutrition awareness further support market expansion.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 4,548.7 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 6.2% | 2032 Value Projection: | USD 6,939 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
AbbVie Inc., Danone, Fresenius Kabi AG, GENTAG, Inc., GSK plc., Nestlé SA, Nutricia, Sun Pharmaceutical Industries Ltd, Pfizer Inc., Sanofi, Otsuka Holdings Co., Ltd., and Otsuka Holdings Co., Ltd. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
The increasing adoption of inorganic growth strategies such as collaborations is expected to drive the global parenteral nutrition market growth over the forecast period.
For instance, on June 1, 2023, Nestlé Health Science, a subsidiary company of Nestlé SA, announced a collaboration with Indian Association for Parenteral and Enteral Nutrition (IAPEN) to strengthen awareness on Gut Health Management. Through the collaboration, Nestlé Health Science reached out to more than 800 Healthcare Practitioners (HCPs) across 26 chapters of IAPEN.
Increasing product launch by key market players is expected to drive the global parenteral nutrition market. For instance, In November 2020, Otsuka Holdings Co., Ltd., a pharmaceutical company, announced the launch of ENEFLUID Injection, the amino acid, glucose excipient, electrolyte, fat, and water-soluble vitamin injection.
This ENEFLUID is the first peripheral parenteral nutrition solution in Japan that combines fat and water-soluble vitamins in addition to glucose, electrolytes, and amino acids in a dual-chamber bag. By compounding fat, more calories can be administered than the approved glucose, electrolyte, and amino acid infusions, and by compounding nine water-soluble vitamins.
The growing awareness about clinical nutrition among consumers and healthcare professionals is significantly impacting the global parenteral nutrition market. There is a rising understanding that proper clinical nutrition is essential for improving health outcomes, especially for critically ill patients or those undergoing surgery or cancer treatment. Parenteral nutrition helps ensure patients receive adequate nutrients when they are unable to consume food or absorb nutrients orally or enterally.
The global parenteral nutrition market is witnessing a notable shift towards single-dose parenteral nutrition products. With growing preference for convenience and safety, pharmaceutical companies are increasingly investing in the development of ready-to-use single-dose parenteral nutrition bags that eliminate the need for compounding. This trend addresses key concerns regarding contamination risks associated with compounded parenteral nutrition and reduces preparation time for caregivers.
One of the major opportunities for the market is the emergence of enhanced parenteral nutrition solutions which are more effective in delivering optimal nutrition. The development of advanced formulations that can better mimic physiological nutrition absorption is a key focus area among major players. These enhanced formulations help meet the complete nutritional needs of patients more efficiently.
For example, many new products entering the market contain balanced mixtures of carbohydrates, proteins, fats, electrolytes, vitamins, and minerals customized for different clinical conditions and needs. This helps maximize the benefits and minimize the risks associated with parenteral nutrition therapy.
Some of the key players in the global Parenteral Nutrition market are AbbVie Inc., Danone, Fresenius Kabi AG, GENTAG, Inc., GSK plc., Nestlé SA, Nutricia, Sun Pharmaceutical Industries Ltd, Pfizer Inc., Sanofi, Otsuka Holdings Co., Ltd., and Otsuka Holdings Co., Ltd.
*Definition: Parenteral nutrition is the medical term for infusing a specialized form of food through a vein (intravenously). The goal of the treatment is to cure or prevent malnutrition. Parenteral nutrition provides liquid nutrients, including carbohydrates, proteins, fats, vitamins, minerals, and electrolytes. Some people use parenteral nutrition to feed various vitamin or protein supplements through a tube placed into the stomach or small bowel.
Share
Share
About Author
Ghanshyam Shrivastava - With over 20 years of experience in the management consulting and research, Ghanshyam Shrivastava serves as a Principal Consultant, bringing extensive expertise in biologics and biosimilars. His primary expertise lies in areas such as market entry and expansion strategy, competitive intelligence, and strategic transformation across diversified portfolio of various drugs used for different therapeutic category and APIs. He excels at identifying key challenges faced by clients and providing robust solutions to enhance their strategic decision-making capabilities. His comprehensive understanding of the market ensures valuable contributions to research reports and business decisions.
Ghanshyam is a sought-after speaker at industry conferences and contributes to various publications on pharma industry.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
Schedule a meeting with report Author
